Executive Summary
This week's digest highlights: Monitor for vasospasm during endovascular stroke procedures, especially in younger smokers with M2 occlusions, and consider intraarterial nimodipine as a treatment strategy. Utilize the chopsticks mononostril approach with sphenoid sinus cranialization for select skull base tumors to enhance patient quality of life while ensuring effective resection. In cases of noncontiguous...
Owen briefs you on what matters in this week's digest.
Think chief-resident chalk talk: what matters, what changes practice, and where to spend your reading time.
Endovascular / Vascular
Vasospasm During Endovascular Treatment of Ischemic Stroke: Associated Factors, Impact on Outcomes, and the Effect of Intraarterial Nimodipine.
Research • Endovascular / Vascular • Stroke • 2025-12-03
Monitor for vasospasm during endovascular stroke procedures, particularly in younger smokers with M2 occlusions, and consider intraarterial nimodipine when it occurs.
OVasospasm during endovascular treatment for ischemic stroke is linked to poorer outcomes and increased mortality, necessitating vigilant monitoring and consideration of intraarterial nimodipine, particularly in younger smokers with M2 occlusions.
Study snapshot
Design
Multicenter, prospective, observational registry
Population
Patients with acute ischemic stroke undergoing endovascular treatment at 25 German centers
Intervention
Endovascular treatment with assessment of vasospasm occurrence
Comparator
Patients without vasospasm
Primary outcome
Distribution of modified Rankin Scale scores at 90 days
Why it matters
Vasospasm during endovascular stroke treatment was known to occur in up to 20% of patients, but its clinical impact remained controversial, and the efficacy of intraarterial nimodipine was uncertain. This large prospective multicenter registry demonstrates that vasospasm is associated with worse functional outcomes and higher mortality, and identifies specific patient and procedural factors that increase risk. Clinicians should now regard vasospasm as a serious procedural complication, monitor high-risk patients more closely, and consider intraarterial nimodipine as it may mitigate neurological deterioration.
Practice change
May support more aggressive monitoring for vasospasm during endovascular stroke procedures and consideration of intraarterial nimodipine when it occurs.
More context
Key details
- 17,985 patients from the German Stroke Registry-Endovascular Treatment (mean age 73.6 years)
- 578 patients (3.2%) had vasospasm reported during endovascular treatment
- 300 of vasospasm patients (58.4%) received intraarterial nimodipine
- Vasospasm associated with shift toward worse modified Rankin Scale scores at 90 days
- Intraarterial nimodipine associated with reduced early neurological deterioration
High-yield
Vasospasm during endovascular treatment is associated with worse outcomes and increased mortality.
Clinical context
Vasospasm occurs in up to 20% of patients with acute ischemic stroke undergoing endovascular treatment, but its clinical impact remains controversial.
Limitations
Observational design limits causal inference despite statistical adjustmentsVasospasm detection and nimodipine administration were not standardized across 25 centers
Methodological critique
Observational design with potential for unmeasured confounding despite statistical adjustments.
Teaching pearl
When you see vasospasm during a thrombectomy, don't dismiss it as a minor nuisance—it's associated with worse outcomes. Consider nimodipine administration, especially in younger smokers with distal occlusions requiring multiple passes.
Funding and COI
Not stated
Tumor / Skull Base
Chopsticks mononostril approach with sphenoid sinus cranialization and septal mucosa suturing: a new minimally invasive concept and closure technique for endoscopic endonasal approaches.
Research • Tumor / Skull Base • Journal of neurosurgery • 2026-03-13
Consider the chopsticks mononostril approach with sphenoid sinus cranialization for selected skull base lesions as it preserves nasal anatomy and quality of life while maintaining resection efficacy.
OThe chopsticks mononostril approach with sphenoid sinus cranialization may offer a promising alternative for select skull base lesions by minimizing nasal morbidity and preserving quality of life, though further studies are needed to validate its efficacy and safety compared to traditional methods.
Study snapshot
Design
Retrospective cohort study
Population
82 consecutive patients undergoing endoscopic endonasal approach for paraclival and craniovertebral junction lesions
Intervention
Chopsticks mononostril approach with sphenoid sinus cranialization and septal mucosa suturing
Comparator
Traditional extended endoscopic endonasal approach with nasoseptal flap
Primary outcome
Surgical outcomes and postoperative results including health-related quality of life
Why it matters
Traditional extended endoscopic endonasal approaches often require resection of normal nasal structures and harvesting of pedicled flaps, which can cause significant nasal morbidity and impact quality of life. This study suggests that a minimally invasive chopsticks mononostril approach with sphenoid sinus cranialization provides comparable resection rates and CSF leak rates while significantly better preserving health-related quality of life. Surgeons performing endoscopic skull base surgery could consider this less invasive technique as an alternative to traditional extended approaches, particularly when quality of life preservation is a priority.
Practice change
Could consider the chopsticks mononostril approach as a less invasive alternative to traditional extended endoscopic approaches for selected skull base lesions.
More context
Key details
- 82 consecutive patients with paraclival and craniovertebral junction lesions
- 41 patients treated with chopsticks mononostril approach using sphenoid sinus cranialization technique (SSCT)
- 41 historical controls treated with extended EEA using nasoseptal flap technique (NSFT)
High-yield
The chopsticks mononostril approach achieved gross-total or subtotal resection in 97.6% of patients with significantly better health-related quality of life scores compared to traditional extended approaches using nasoseptal flaps.
Clinical context
Extended endoscopic endonasal approaches and pedicled flaps represented major advancements for skull base lesion removal, but resection of normal nasal structures and flap harvesting can result in significant nasal morbidity.
Limitations
Retrospective design with historical controls introduces potential selection biasSingle-center experience limits generalizability
Methodological critique
Retrospective design with historical controls limits causal inference.
Teaching pearl
When planning an endoscopic skull base approach, remember that 'less is more'—the chopsticks technique with angled endoscopes lets you navigate around corners rather than removing them, preserving anatomy and patient quality of life.
Funding and COI
NSF
Spine
Clinical and Radiological Outcomes of Skip-Level Cervical Disk Arthroplasty.
Research • Spine • Neurosurgery • 2026-03-10
For noncontiguous cervical disk pathologies requiring surgery, consider CDA over ACDF to preserve motion and potentially reduce adjacent segment disease.
OIn cases of noncontiguous cervical disk pathologies, consider cervical disk arthroplasty over anterior cervical discectomy and fusion to potentially preserve motion and reduce adjacent segment disease, though the evidence remains limited.
Study snapshot
Design
Retrospective cohort study
Population
Patients with symptomatic noncontiguous disk herniations or spondylosis of subaxial cervical spine
Intervention
Skip-level cervical disk arthroplasty (CDA)
Comparator
Skip-level anterior cervical diskectomy and fusion (ACDF)
Primary outcome
Clinical and radiological outcomes including ASD incidence and range of motion
Why it matters
Previously, skip-level cervical surgery for noncontiguous pathologies often involved ACDF, but concerns existed about adjacent segment disease (ASD) at the skipped level. This study suggests that skip-level CDA preserves motion at both indexed and skipped levels with lower ASD rates compared to ACDF. Surgeons could consider CDA over ACDF for noncontiguous cervical disk herniations or spondylosis to potentially reduce ASD and maintain motion.
Practice change
Could consider CDA over ACDF for noncontiguous cervical pathologies to potentially reduce adjacent segment disease.
More context
Key details
- Retrospective analysis of consecutive patients with noncontiguous cervical disk herniations or spondylosis
- Minimum 2-year follow-up for all patients
- CDA preserved overall cervical ROM while ACDF nearly eliminated it
- One ACDF patient required reoperation for symptomatic ASD at skipped level; no CDA reoperations
- Complication rates were comparable between groups
- Both procedures restored cervical lordosis effectively
High-yield
See source article for primary outcome data.
Clinical context
Skip-level cervical surgery for noncontiguous pathologies theoretically has higher ASD risk, especially between two ACDF constructs. The comparison between CDA and ACDF for these cases remains unclear.
Limitations
Retrospective design with inherent selection bias (CDA patients were significantly younger)Small sample size limits generalizability and statistical power
Methodological critique
Retrospective design with significant age difference between groups introduces selection bias.
Teaching pearl
When planning skip-level cervical surgery, remember that CDA preserves motion at both operated and skipped levels, potentially reducing adjacent segment disease compared to ACDF—especially important for younger patients who may face decades of spinal function.
Funding and COI
Not stated
Basic Science
Post-resection delivery of a TLR7/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice.
Research • Basic Science • Nature communications • 2025-09-29
Preclinical evidence; no immediate practice change pending clinical validation.
OWhile this preclinical study suggests that local delivery of a TLR7/8 agonist via biodegradable scaffolds may enhance immune-mediated glioblastoma clearance, the findings are not directly translatable to clinical practice and require further validation in human trials.
Study snapshot
Design
Preclinical animal study
Population
Mice with orthotopic GL261 or CT2A glioblastoma tumors
Intervention
Resiquimod-loaded biodegradable polymer scaffold implanted in resection cavity
Comparator
Blank scaffold or bolus resiquimod injection
Primary outcome
Survival, tumor clearance, and immune memory formation
Why it matters
GBM recurrence after resection remains nearly universal despite current therapies, and systemic immunotherapy has shown limited success. This preclinical study demonstrates that local, sustained delivery of a TLR7/8 agonist via biodegradable scaffold after resection can achieve tumor clearance and immune memory in mouse models. While not immediately applicable to humans, this approach suggests a promising strategy for enhancing perioperative immunotherapy in GBM.
Practice change
Does not change current clinical practice but may inform future translational work.
More context
Key details
- Preclinical study using GL261 and CT2A orthotopic mouse GBM models
- Biodegradable acetalated dextran scaffold provided sustained resiquimod release over 7 days
- Scaffold increased brain drug concentration 19-fold compared to bolus injection
- Long-term survivors demonstrated protection from contralateral tumor rechallenge
- Treatment increased effector memory T cells and granzyme B+ CD8+ T cells in brain
- Well-tolerated with only transient weight loss
High-yield
In mouse GBM models, resiquimod-loaded biodegradable scaffolds implanted post-resection achieved durable tumor suppression in 50-80% of mice and conferred protective immune memory against rechallenge.
Clinical context
GBM has near-universal recurrence despite standard therapy. Local drug delivery systems like Gliadel® have limitations, and immunotherapy faces challenges due to GBM's immunosuppressive microenvironment.
Limitations
Preclinical mouse models may not translate to human GBM biology and immune responsesSmall sample sizes in experimental groups limit statistical robustness
Methodological critique
Small sample sizes in mouse groups limit statistical power and generalizability.
Teaching pearl
This study highlights how local, sustained immunotherapy delivery to the resection cavity can capitalize on the perioperative immune window—reduced tumor burden and disrupted microenvironment—to potentially overcome GBM's immunosuppressive barriers.
Funding and COI
Not stated